Home/Filings/4/0001181431-12-008916
4//SEC Filing

MARTIN J TYLER 4

Accession 0001181431-12-008916

CIK 0001029142other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 8:03 PM ET

Size

12.3 KB

Accession

0001181431-12-008916

Insider Transaction Report

Form 4
Period: 2012-02-13
MARTIN J TYLER
VP Clinical Development & CMO
Transactions
  • Award

    Common shares

    2012-02-13$0.58/sh+150,000$87,000150,000 total
  • Award

    Common shares

    2012-02-13$1.72/sh+32,848$56,499182,848 total
  • Exercise/Conversion

    Option (Right to Buy)

    2012-02-1375,000225,000 total
    Exercise: $0.58From: 2010-02-27Exp: 2019-02-26Common Stock (75,000 underlying)
  • Exercise/Conversion

    Options (Right to Buy)

    2012-02-1375,000150,000 total
    Exercise: $0.58From: 2011-02-27Exp: 2019-02-26Common Stock (75,000 underlying)
  • Exercise/Conversion

    Options (Right to Buy)

    2012-02-1332,848484,396 total
    Exercise: $1.72From: 2011-08-25Exp: 2020-08-24Common Stock (32,848 underlying)
Footnotes (2)
  • [F1]Not applicable.
  • [F2]On February 13, 2012, Dr. Martin exercised certain of his outstanding options for cash. No shares were sold in the market in connection with this exercise.

Issuer

DYNAVAX TECHNOLOGIES CORP

CIK 0001029142

Entity typeother

Related Parties

1
  • filerCIK 0001234388

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 8:03 PM ET
Size
12.3 KB